You're their **front line.**
Protect the **central line.**

DEFENCATH®
Taurolidine and Heparin Catheter Lock Solution
Limited Population

THE FIRST AND ONLY FDA-APPROVED ANTIMICROBIAL CLS IN THE US

indicated to reduce the incidence of CRBSIs in adult patients with kidney failure receiving chronic HD through a CVC. This drug is indicated for use in a limited and specific population of patients.

Limitations of Use

The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.

Not Actual Size

DefenCath CLS is available as a 3 mL single-dose vial containing taurolidine 40.5 mg/3 mL (13.5 mg/mL), and heparin 3,000 USP Units/3 mL (1,000 USP Units/mL).

- DefenCath is for instillation into CVCs only
- DefenCath is **not** intended for systemic administration
- Do **not** use DefenCath as a catheter lock flush product

CLS = catheter lock solution; CRBSI = catheter-related bloodstream infection.

INDICATIONS AND USAGE

LIMITED POPULATION: DEFENCATH® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Limitations of Use

The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

DEFENCATH is contraindicated in patients with:

- Known heparin-induced thrombocytopenia (HIT).
- Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DEFENCATH), or pork products.

Please see additional Important Safety Information throughout and the full Prescribing Information.

Scan the QR code to learn more, or visit DefenCath.com

DefenCath Reduced the Risk of CRBSIs by 71% Compared to Heparin Control



*log-rank test

In the LOCK-IT-100 pivotal Phase 3 clinical trial, DefenCath reduced the risk of CRBSIs by 71% compared to heparin (1000 USP Units/mL) when used as a CLS in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter.

Selected adverse reactions occurring in ≥2% of patients receiving DefenCath or heparin as a CLS in the clinical trial:

- DefenCath: hemodialysis catheter malfunction (17%), hemorrhage/bleeding (7%), nausea (7%), vomiting (6%), dizziness (6%), musculoskeletal chest pain (3%), and thrombocytopenia (2%)
- Heparin: hemodialysis catheter malfunction (12%), hemorrhage/bleeding (9%), nausea (11%), vomiting (8%), dizziness (4%), musculoskeletal chest pain (2%), and thrombocytopenia (1%)

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS

- **Heparin-Induced Thrombocytopenia (HIT):** HIT was reported in patients using heparin, a component of DEFENCATH, as a catheter lock solution. If HIT occurs, discontinue DEFENCATH and institute appropriate supportive measures.
- **Drug Hypersensitivity:** Drug hypersensitivity reactions have been reported in patients using heparin, a component of DEFENCATH, as a catheter lock solution. If a hypersensitivity reaction occurs, discontinue DEFENCATH and institute appropriate supportive measures.

ADVERSE REACTIONS

The most frequently reported adverse reactions occurring in ≥2% of patients using DEFENCATH as a CLS or hemodialysis were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.

To report SUSPECTED ADVERSE REACTIONS, contact CorMedix Inc at 1-844-424-6345 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout and the full Prescribing Information.

Please scan the QR code for full Prescribing Information

Reference: DefenCath® (taurolidine and heparin) catheter lock solution Prescribing Information, CorMedix, Berkeley Heights, New Jersey.

CorMedix®

DEFENCATH® Taurolidine and Heparin Catheter Lock Solution | Limited Population